Elanco Competitors

ELAN Stock

USD 24.98 0.22 0.87%

Elanco Animal Health competes with Cencora, Regeneron Pharmaceuticals, IDEXX Laboratories, Haleon Plc, and Cigna Corp; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Elanco Animal competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Elanco Animal to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Elanco Animal Correlation with its peers.

Elanco Animal vs Argenx NV Correlation

Very good diversification

The correlation between Elanco Animal Health and ARGX is -0.46 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Elanco Animal Health and ARGX in the same portfolio, assuming nothing else is changed.

Moving against Elanco Stock

0.65	21P	Aurora Cannabis	Pair Corr
0.4	NXS	Next Science Earnings Call This Week	Pair Corr
0.32	WEED	Canopy Growth Corp	Pair Corr

As of the 21st of February 2026, Return On Tangible Assets is likely to grow to 0.09. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Elanco Animal's Intangible Assets are very stable compared to the past year. As of the 21st of February 2026, Return On Tangible Assets is likely to grow to 0.09, while Total Assets are likely to drop about 13.6 B.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
23.18	25.07	26.96

Details

Intrinsic

Valuation

Low	Real	High
22.48	27.18	29.07

Details

Naive

Forecast

Low	Next	High
23.51	25.40	27.30

Details

15 Analysts

Consensus

Low	Target	High
23.87	26.23	29.12

Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Elanco Animal. Your research has to be compared to or analyzed against Elanco Animal's peers to derive any actionable benefits. When done correctly, Elanco Animal's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Elanco Animal Health.

Elanco Animal Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Elanco Animal and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Elanco and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Elanco Animal Health does not affect the price movement of the other competitor.

	COR	REGN	IDXX	HLN	CI	ELV	BDX	ARGX
COR		0.22	-0.11	0.44	0.4	-0.23	0.25	0.11	COR
REGN	0.22		-0.27	0.56	0.68	0.12	0.32	-0.37	REGN
IDXX	-0.11	-0.27		-0.84	-0.56	0.15	-0.49	0.42	IDXX
HLN	0.44	0.56	-0.84		0.78	-0.12	0.52	-0.44	HLN
CI	0.4	0.68	-0.56	0.78		0.08	0.62	-0.48	CI
ELV	-0.23	0.12	0.15	-0.12	0.08		0.12	-0.67	ELV
BDX	0.25	0.32	-0.49	0.52	0.62	0.12		-0.41	BDX
ARGX	0.11	-0.37	0.42	-0.44	-0.48	-0.67	-0.41		ARGX
	COR	REGN	IDXX	HLN	CI	ELV	BDX	ARGX

High positive correlations

CI	+ 0.78	HLN
CI	+ 0.68	REGN
BDX	+ 0.62	CI
HLN	+ 0.56	REGN
BDX	+ 0.52	HLN
HLN	+ 0.44	COR

High negative correlations

HLN	- 0.84	IDXX
ARGX	- 0.67	ELV
CI	- 0.56	IDXX
BDX	- 0.49	IDXX
ARGX	- 0.48	CI
ARGX	- 0.44	HLN

Risk-Adjusted Indicators

There is a big difference between Elanco Stock performing well and Elanco Animal Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Elanco Animal's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
COR	1.21	(0.05)	0.00	(0.27)	0.00	0.00	2.01	(2.62)	10.81
REGN	1.41	0.00	(0.01)	0.07	1.48	(1.81)	3.19	(2.61)	8.44
IDXX	1.09	(0.33)	0.00	(0.39)	0.00	0.00	1.83	(3.18)	8.47
HLN	0.90	0.25	0.18	4.76	0.74	(1.05)	1.65	(1.33)	5.40
CI	1.18	0.01	0.00	0.08	1.25	(1.39)	2.56	(2.06)	7.36
ELV	1.52	0.00	0.01	0.07	2.95	(1.58)	3.20	(2.45)	19.95
BDX	1.20	0.25	0.24	0.32	0.69	(1.53)	3.22	(1.77)	7.13
ARGX	1.17	(0.11)	0.00	1.24	0.00	0.00	2.29	(3.07)	7.34

Cross Equities Net Income Analysis

Compare Elanco Animal Health and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income Over Time

Select Fundamental

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
BDX	88 M	1.2 B	1.3 B	1.2 B	695 M	976 M	1.1 B	311 M	1.2 B	874 M	2.1 B	1.8 B	1.5 B	1.7 B	1.7 B	1.9 B	2 B

Elanco Animal Health and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Elanco Animal Health financial statement analysis. It represents the amount of money remaining after all of Elanco Animal Health operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Elanco Animal Competitive Analysis

The better you understand Elanco Animal competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Elanco Animal's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Elanco Animal's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	ELAN	COR	REGN	IDXX	HLN	CI	ELV	BDX	ARGX
	0.87 24.98 Elanco	0.55 361.08 Cencora	0.23 779.67 Regeneron	0.78 635.66 IDEXX	1.44 11.27 Haleon	1.96 280.31 Cigna	1.51 342.93 Elevance	1.60 185.39 Becton	0.34 844.41 Argenx
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady
Market Performance (90 Days Performance)	Mild	Weakest	Weak	Weakest	Solid	Soft	Soft	Solid	Weakest
Odds of Financial Distress (Probability Of Bankruptcy)	Tiny	Low	Tiny	Tiny	Low	Low	Tiny	Tiny	Tiny
Current Valuation (Equity Enterprise Value)	Under Valued	Fairly Valued	Fairly Valued	Fairly Valued	Under Valued	Under Valued	Fairly Valued	Under Valued	Fairly Valued
Buy or Sell Advice (Average Analysts Consensus)	Buy	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Buy	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Buy	Strong Sell	Hold	Strong Hold	Strong Hold	Hold	Cautious Hold	Strong Buy	Strong Sell
Current Ratio	1.96	0.58	5.36	0.89	3.43	0.83	1.35	1.35	11.07
Net Asset	12.61 B	76.59 B	40.56 B	3.35 B	34.31 B	155.88 B	121.49 B	55.33 B	6.2 B
Profit Margin	0.0078	0.005	0.31	0.25	0.14	0.0217	0.0284	0.0801	0.42
EBITDA	1.49 B	3.74 B	5.82 B	1.47 B	2.51 B	12.17 B	9.66 B	4.96 B	105.17 M
Operating Margin	0.0238	0.0118	0.23	0.29	0.22	0.0335	0.0154	0.13	0.3
Current Valuation	16.01 B	73.5 B	79.01 B	50.92 B	60.22 B	104.8 B	99.1 B	68.82 B	47.36 B
Price To Book	1.85	36.78	2.72	31.3	2.3	1.84	1.74	1.98	8.34
Retained Earnings	(1.95 B)	6.53 B	35.8 B	5.33 B	27.27 B	43.52 B	35.39 B	16.62 B	(1.57 B)
Current Asset	2.45 B	19.09 M	2.92 B	821.63 M	N/A	13.51 B	N/A	6.37 B	78.94 M
Five Year Return	N/A	3.65	N/A	N/A	N/A	0.42	1.13	1.29	N/A
Beta	1.86	0.69	0.41	1.66	0.22	0.28	0.5	0.28	-0.17
Number Of Employees	9 K	47 K	15.41 K	11 K	24.56 K	71.3 K	96.13 K	70 K	1.6 K
Shares Outstanding	496.86 M	194.53 M	103.9 M	79.85 M	4.45 B	263.46 M	220.7 M	284.47 M	61.88 M
Cash Flow From Operations	541 M	3.88 B	4.98 B	1.18 B	2.3 B	10.36 B	4.29 B	3.43 B	(82.75 M)
Annual Yield	N/A	0.0067	0.0048	N/A	0.0166	0.0218	0.0198	0.0227	N/A
Total Debt	4.32 B	10.75 B	2.71 B	847.84 M	10.1 B	31.97 B	32.05 B	19.18 B	39.05 M
Return On Equity	0.0054	1.33	0.15	0.66	0.0938	0.15	0.13	0.0696	0.25
Return On Asset	0.0115	0.0333	0.0591	0.26	0.0461	0.0403	0.0435	0.0408	0.0483
Number Of Shares Shorted	23.23 M	4.43 M	2.18 M	1.81 M	17.84 M	4.61 M	3.6 M	6.69 M	1.82 M
Book Value Per Share	13.58	9.81	304.65	20.09	2.38	153.73	198.81	88.79	99.66
Current Liabilities	805.47 M	111.82 M	811.16 M	856.76 M	N/A	18.21 B	N/A	4.4 B	30.84 M
Total Asset	12.61 B	76.59 B	40.56 B	3.35 B	34.31 B	155.88 B	121.49 B	55.33 B	6.2 B
Debt To Equity	0.87	N/A	0.13	3.28	0.38	0.74	0.66	0.64	0.003
Short Ratio	5.06	4.02	2.49	3.9	2.27	3.09	2.15	3.91	4.66
Target Price	26.23	403.79	868.04	750.23	11.93	332.62	387.85	195.38	1027.24
Last Dividend Paid	N/A	2.25	3.52	N/A	0.068	6.04	6.84	4.17	N/A
Shares Owned By Institutions	98.93	94.49	90.8	95.35	12.75	92.52	93.26	96.36	49.01
Market Capitalization	12.52 B	69.86 B	82.71 B	50.46 B	49.47 B	76.38 B	76.84 B	67.17 B	52.43 B
Price To Earning	241.75	82.16	15.51	61.31	18.06	13.93	19.27	45.86	5.54
Price To Earnings To Growth	4.35	0.86	1.53	3.74	3.21	0.59	1.35	1.33	0.9
Price To Sales	2.73	0.21	5.77	11.73	4.49	0.28	0.39	3.06	14.24
Net Income	338 M	1.57 B	4.5 B	1.06 B	1.44 B	3.78 B	5.66 B	1.68 B	833.04 M
Earnings Per Share	0.07	8.33	41.47	13.06	0.45	22.19	25.21	6.12	23.38
Shares Owned By Insiders	1.07	4.22	1.98	0.71	0.014	1.62	0.17	0.39	N/A
Revenue	4.44 B	321.33 B	14.34 B	4.3 B	11.23 B	274.95 B	199.12 B	21.84 B	2.19 B
Working Capital	1.9 B	(5.58 B)	13.65 B	331.98 M	(94 M)	(4.7 B)	N/A	942 M	4.21 B
Cash And Equivalents	463 M	4.36 B	7.02 B	114.36 M	684 M	7.55 B	9.49 B	641 M	2.6 B
Cash Per Share	0.98	0.08	65.75	1.37	0.29	16.96	150.32	9.02	47.17
Gross Profit	2.52 B	11.77 B	6.39 B	2.66 B	7 B	25.56 B	50.9 B	10.26 B	2.02 B
Day Typical Price	25.02	359.49	776.85	633.01	11.21	281.24	343.15	184.16	841.77
Accumulation Distribution	54839.28	0.0136	0.0139	0.0202	0.016	0.0317	0.0315	0.0211	0.0277
Market Facilitation Index	N/A	4.9	10.88	12.92	0.18	9.08	10.97	3.91	23.59
Daily Balance Of Power	(0.45)	0.402	(0.16)	0.3816	0.8889	(0.62)	(0.48)	0.7468	(0.12)
Period Momentum Indicator	(0.22)	1.97	(1.77)	4.93	0.16	(5.61)	(5.25)	2.92	(2.85)
Rate Of Daily Change	0.99	1.01	1.0	1.01	1.01	0.98	0.98	1.02	1.0
Day Median Price	25.04	358.69	775.44	631.68	11.18	281.7	343.27	183.55	840.46
Price Action Indicator	(0.16)	3.37	3.34	6.44	0.17	(4.20)	(2.96)	3.3	2.53
Relative Strength Index	52.05	69.93	48.76	21.59	68.32	44.59	40.55	48.53	51.92
Coefficient Of Variation	709.36	(6,996)	3165.63	(564.99)	440.49	2077.85	2367.36	497.2	(1,484)
Mean Deviation	1.47	1.21	1.41	1.09	0.898	1.18	1.52	1.2	1.17
Jensen Alpha	0.1802	(0.05)	4.0E-4	(0.33)	0.2483	0.0084	(0)	0.2453	(0.11)
Total Risk Alpha	0.0848	(0.22)	(0.12)	(0.42)	0.1453	(0.08)	(0.14)	0.1653	(0.26)
Sortino Ratio	0.1074	N/A	(0.01)	N/A	0.1759	(0)	0.0093	0.2394	N/A
Downside Variance	3.3	N/A	2.33	N/A	1.06	1.81	9.49	1.04	N/A
Standard Deviation	1.96	1.98	1.83	1.52	1.15	1.55	2.58	1.61	1.58
Kurtosis	0.902	7.75	0.362	2.11	0.1137	0.7212	16.3	2.0	0.7148
Potential Upside	3.66	2.01	3.19	1.83	1.65	2.56	3.2	3.22	2.29
Treynor Ratio	0.2193	(0.27)	0.0711	(0.39)	4.76	0.0811	0.0674	0.32	1.24
Maximum Drawdown	10.56	10.81	8.44	8.47	5.4	7.36	19.95	7.13	7.34
Variance	3.82	3.9	3.34	2.3	1.33	2.4	6.67	2.6	2.49
Market Risk Adjusted Performance	0.2293	(0.26)	0.0811	(0.38)	4.77	0.0911	0.0774	0.33	1.25
Risk Adjusted Performance	0.1136	(0)	0.0299	(0.13)	0.1765	0.0418	0.0393	0.1586	(0.05)
Skewness	(0.16)	(1.12)	0.437	(0.81)	0.2994	0.4674	(2.68)	1.34	(0.30)
Semi Deviation	1.57	N/A	1.48	N/A	0.7433	1.25	2.95	0.6911	N/A
Information Ratio	0.0998	(0.06)	(0.01)	(0.23)	0.1573	(0)	0.0111	0.1512	(0.12)
Value At Risk	(2.79)	(2.62)	(2.61)	(3.18)	(1.33)	(2.06)	(2.45)	(1.77)	(3.07)
Expected Short fall	(1.73)	N/A	(1.81)	N/A	(1.05)	(1.39)	(1.58)	(1.53)	N/A
Downside Deviation	1.82	N/A	1.53	N/A	1.03	1.35	3.08	1.02	N/A
Semi Variance	2.47	N/A	2.2	N/A	0.5525	1.57	8.72	0.4777	N/A

Elanco Animal Competition Performance Charts

Five steps to successful analysis of Elanco Animal Competition

Elanco Animal's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Elanco Animal Health in relation to its competition. Elanco Animal's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Elanco Animal in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Elanco Animal's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Elanco Animal Health, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Elanco Animal position

In addition to having Elanco Animal in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Healthcare Funds Thematic Idea Now

Healthcare Funds

Funds or Etfs investing in medical and healthcare goods or services as well as hospital management or maintenance organizations. The Healthcare Funds theme has 43 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Funds Theme or any other thematic opportunities.

View All Next

Launch

When determining whether Elanco Animal Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Elanco Animal's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Elanco Animal Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Elanco Animal Health Stock:

How To Invest In Elanco

Details

Is Elanco Stock a good investment?

Details

What is Elanco Animal's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Elanco Animal Correlation with its peers.

You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Will Pharmaceuticals sector continue expanding? Could Elanco diversify its offerings? Factors like these will boost the valuation of Elanco Animal. Projected growth potential of Elanco fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Elanco Animal data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Quarterly Earnings Growth

1.167

Earnings Share

0.07

Revenue Per Share

9.261

Quarterly Revenue Growth

0.104

Return On Assets

0.0115

The market value of Elanco Animal Health is measured differently than its book value, which is the value of Elanco that is recorded on the company's balance sheet. Investors also form their own opinion of Elanco Animal's value that differs from its market value or its book value, called intrinsic value, which is Elanco Animal's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Elanco Animal's market value can be influenced by many factors that don't directly affect Elanco Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

It's important to distinguish between Elanco Animal's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Elanco Animal should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Elanco Animal's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Elanco Competitors

Elanco Animal vs Argenx NV Correlation

Very good diversification

Moving against Elanco Stock

Specify up to 10 symbols:

Elanco Animal Competition Correlation Matrix

High positive correlations

High negative correlations

Risk-Adjusted Indicators

Cross Equities Net Income Analysis

Elanco Animal Health and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income description

Elanco Animal Competitive Analysis

Elanco Animal Competition Performance Charts

Five steps to successful analysis of Elanco Animal Competition

Complement your Elanco Animal position

Did You Try This Idea?

Run Healthcare Funds Thematic Idea Now

Healthcare Funds

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY